2. Search Result
Search Result
Results for "

Natriuresis

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2469
    Brain Natriuretic Peptide-45, mouse

    BNP-45, mouse

    		 Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    Brain Natriuretic Peptide-45, mouse (BNP-45, mouse) is a 45-amino-acid peptide derived from the mouse BNP prohormone, which exhibits natriuretic, diuretic, and vasoactive effects. Brain Natriuretic Peptide-45, mouse contains all amino acid residues deemed critical for the biological activity of natriuretic peptides. Brain Natriuretic Peptide-45, mouse possesses hypotensive and diuretic activities .
    Brain Natriuretic Peptide-45, mouse
  • HY-122560A
    VU0134992 hydrochloride
    4 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992 hydrochloride
  • HY-122560
    VU0134992
    4 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992
  • HY-15195
    Avosentan

    Ro 67-0565; SPP-301

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
    Avosentan
  • HY-106616
    Muzolimine

    BAY-g 2821; Edrul

    		 Sodium Channel Cardiovascular Disease
    Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
    Muzolimine
  • HY-139037
    8-Aminoguanine

    		Endogenous Metabolite Metabolic Disease
    8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
    8-Aminoguanine
  • HY-124404
    12(R)-HETE

    		Aryl Hydrocarbon Receptor Na+/K+ ATPase Prostaglandin Receptor Inflammation/Immunology
    12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation .
    12(R)-HETE
  • HY-106616R
    Muzolimine (Standard)

    BAY-g 2821 (Standard); Edrul (Standard)

    		 Sodium Channel Reference Standards Cardiovascular Disease
    Muzolimine (Standard) is the analytical standard of Muzolimine. This product is intended for research and analytical applications. Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
    Muzolimine (Standard)
  • HY-W771063
    8-Aminoguanine-13C2,15N

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    8-Aminoguanine- 13C2, 15N is the 13C- and 15N-labeled 8-Aminoguanine (HY-139037). 8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
    8-Aminoguanine-13C2,15N
  • HY-124687
    ROMK-IN-32

    		Potassium Channel Cardiovascular Disease
    ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM .
    ROMK-IN-32
  • HY-122282
    AZ11657312

    		Angiotensin Receptor Cardiovascular Disease
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
    AZ11657312
  • HY-15195R
    Avosentan (Standard)

    Ro 67-0565 (Standard); SPP-301 (Standard)

    		 Reference Standards Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
    Avosentan (Standard)
  • HY-19200
    RB-105

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    RB-105 is an inhibitor of angiotensin-converting enzyme (ACE) (Ki = 4.2 nM) and neutral endopeptidase (NEP) (Ki = 1.7 nM). RB-105 after inhibiting ACE reduces the production of Ang II and increase the level of bradykinin. RB-105 after inhibiting NEP increases the level of natriuretic peptide and further increases the level of bradykinin, thereby generating a powerful synergistic effect. RB-105 has significant antihypertensive and natriuretic effects in both spontaneously hypertensive rats and normal blood pressure rats. RB-105 can be used for research on hypertension .
    RB-105
  • HY-182635
    ICI 147798

    		Adrenergic Receptor Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    ICI 147798 is an orally effective β-adrenoceptor antagonist with a pKB of 9.1 (in guinea pig right atrium) and 8.8 (in guinea pig trachea). ICI 147798 acts as a diuretic and intraocular pressure-lowering agent. ICI 147798 blocks β-adrenoceptors, inhibits isoproterenol-induced tachycardia and vasodepressor responses, exhibits slowly dissociating, insurmountable antagonism against β1-adrenoceptors, and shows surmountable competitive antagonism against β2-adrenoceptors. ICI 147798 induces natriuresis and kaliuresis, inhibits sodium transport, and reduces intraocular pressure .
    ICI 147798

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: